Oncology and Xenograft Studies

We have evaluated many potential anti-cancer compounds in research models. Our in-house expertise allows us to optimally design studies that provide critical preclinical efficacy data and pharmacology assessments. CBI provides a variety of validated cell lines and specialized methods for the assessment of anti-tumor agents  both in vitro and as xenografts.

Oncology Pharmacology Models

  • Validated cell lines
  • Subcutaneous, intravenous and orthotopic implantation, including infusion
  • Immunocompromised and immunocompetent models, including knockout, transgenic and syngeneic
  • Species include mice, rats and rabbits (VX2 line)
  • Customized and specially licensed cell lines and custom tumor cells lines
  • Other models and customized studies can be optimized and are available upon request
  • Computerized digital data collection

Oncology Toxicology and Pharmacokinetics

CBI provides both GLP and nonGLP IND-enabling toxicology and pharmacokinetic studies with oncology products in multiple species, including routine,  investigative and specialized toxicology,  all routes of administration,  maximization of test article effectiveness and minimum effective dosage, and  comparison of formulation and routes of administration.

Oncology Histopathology

CBI offers histopathologic slide preparation and histopathologic assessment of tissues for both pharmacology and toxicology studies using routine histopathology, special stains, immunohistochemistry, in situ, immunofluorescence, TCR, confocal microscopy and digital image analysis.   For GLP studies, we offer a validated pathology data acquisition system (StarTox) and complete reports suitable for regulatory submission.  We have a complete tissue bank with all species and a large number of human and animal tissues available for histopathology and tissue cross reactivity studies.

Immunotherapy

Many new oncology therapeutics are immunotherapeutic agents.  While very active, these therapies are known to have deep and unpredictable pharmacologic effects.  CBI has strong capabilities and experience with the toxicology and pharmacology of oncology immunotherapeutics and is able to guide and support our sponsors who are developing immunotherapeutics.

Extensive experience with:

  • Small molecules
  • Biologics
  • Immunotherapy
  • Gene therapy
  • Stem cells
  • Devices and implants
  • Combination products
  • VX2 cell lines

Validated Tumor Cell Lines

BREAST MDA-MB-231, MCF-7, 4T1
COLON Caco-2, HCT-116, COL 205, L5174T Carcinoma
LUNG A549, LS174T, Lewis Lung (syngeneic)
PROSTATE LNCAP, PC-3, DU-145
MELANOMA B16F0, MDA-MB-435, B16F10 (syngeneic)
OVARIAN SK-OV-3, OVCAR 3, A2780, Hela
CNS U87-MG
MYELOID Daudi, GRANTA-519, Jeko-1, Kasumi-1, HL-60
PANCREATIC PANC-I, PANC-II, ASPC1
LIVER Milo, Lymphoma

Oncology Services

  • Angiogenesis, gene therapy, nanoparticle and stem cell capabilities
  • Maximization of test article effectiveness and minimum effective dosage
  • Combination therapy
  • Subcutaneous, orthotopic, intravenous and other customized routes in tumor induction
  • Comparison of formulation and routes of administration
  • Maximum tolerated dose and pharmacokinetics/pharmacodynamics
  • Supporting capabilities: clinical pathology, immunology, histopathology, immunohistochemistry
carcinoma
Carcinoma demonstrating CD3 expression in new vessels.